

February 10, 2024

To Listing Department, <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), <b>MUMBAI -400 051</b>  <b>Company Code No. AUROPHARMA</b>	To The Corporate Relations Department <b>BSE LIMITED</b> Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> floor, Dalal Street, <b>MUMBAI -400 001</b>  <b>Company Code No. 524804</b>
--	--

Dear Sir / Madam,

**Sub: Outcome of the Board Meeting held on February 10, 2024.**

The Board of Directors of the Company at its meeting held today, February 10, 2024, has transacted, inter alia, the following items of business:

1. Approved the standalone and consolidated Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2023, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Reports issued by the Statutory Auditors.
2. Approved the payment of second interim dividend of 150% i.e. Rs.1.50 (Rupee one and paise fifty) per equity share of Re.1/- each on the equity share capital of the Company. The Company has already fixed February 20, 2024 as the record date for the purpose of payment of interim dividend for the financial year 2023-24. The interim dividend will be paid on or before March 4, 2024.
3. Based on the recommendation of the Nomination and Remuneration Committee and subject to the approval of the members through postal ballot, appointed Dr.(Mrs.) Deepali Pant Joshi (DIN: 07139051) as an Additional Director (Non-executive and Independent) of the Company for a period of 2 (two) years with effect from February 10, 2024.
4. Accepted the resignation of Dr.(Mrs.) Avnit Bimal Singh (DIN: 01316166) as an Independent Director of the Company with effect from close of business hours on February 10, 2024.

The Board meeting commenced at 3.00 p.m. and concluded at 5.15 p.m.

Please take the information on record.

Yours faithfully,  
**For AUROBINDO PHARMA LIMITED**

**B. Adi Reddy**  
**Company Secretary**

Enclosures: as above.

**AUROBINDO PHARMA LIMITED**  
[www.aurobindo.com](http://www.aurobindo.com)

(CIN : L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd.off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad -500038 T.S., INDIA Tel: +91 4023736370/23747340 Fax: +91 4023741080/23746833  
Email: [info@aurobindo.com](mailto:info@aurobindo.com) Website: [www.aurobindo.com](http://www.aurobindo.com)

AUROBINDO PHARMA LIMITED  
(CIN - L24239TG1986PLC015190)  
[www.aurobindo.com](http://www.aurobindo.com)

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India  
Tel: +91 (40) 66721200; Fax: +91 40 23741080; Email: info@aurobindo.com

(All amounts are in ₹ millions, unless otherwise stated)

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023							
	Particulars	Quarter ended			Nine months ended		Year ended
		31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>A</b>	<b>Continuing Operations:</b>						
1	<b>Revenue from operations</b>						
	(a) Net sales/ income from operations	26,638.7	26,484.1	23,365.2	76,758.1	59,998.1	83,715.4
	(b) Other operating income	281.6	203.5	243.9	758.0	509.6	854.6
	<b>Total revenue from operations</b>	<b>26,920.3</b>	<b>26,687.6</b>	<b>23,609.1</b>	<b>77,516.1</b>	<b>60,507.7</b>	<b>84,570.0</b>
2	<b>Other income</b>						
	(a) Foreign exchange gain (net)	556.7	44.7	280.6	938.8	197.4	695.3
	(b) Others	2,754.6	626.1	499.5	3,992.1	1,432.6	3,734.3
	<b>Total other income</b>	<b>3,311.3</b>	<b>670.8</b>	<b>780.1</b>	<b>4,930.9</b>	<b>1,630.0</b>	<b>4,429.6</b>
3	<b>Total income (1+2)</b>	<b>30,231.6</b>	<b>27,358.4</b>	<b>24,389.2</b>	<b>82,447.0</b>	<b>62,137.7</b>	<b>88,999.6</b>
4	<b>Expenses</b>						
	(a) Cost of materials consumed	14,659.3	15,183.3	12,682.8	43,595.2	33,925.7	46,667.2
	(b) Purchase of stock-in-trade	1,550.9	157.7	134.3	1,863.9	740.1	892.3
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(597.6)	(271.2)	42.3	(1,031.3)	(1,905.9)	(2,639.5)
	(d) Employee benefits expense	2,480.8	2,475.1	2,260.8	7,316.5	6,734.9	8,904.7
	(e) Finance costs	612.5	366.9	252.6	1,295.3	428.0	745.7
	(f) Depreciation, amortisation and impairment expense	643.5	657.9	598.7	1,897.7	1,765.8	2,432.6
	(g) Other expenses	4,010.0	3,690.9	4,046.6	11,279.3	11,682.5	15,655.5
	<b>Total expenses</b>	<b>23,359.4</b>	<b>22,260.6</b>	<b>20,018.1</b>	<b>66,216.6</b>	<b>53,371.1</b>	<b>72,658.5</b>
5	<b>Profit before tax from continuing operations (3-4)</b>	<b>6,872.2</b>	<b>5,097.8</b>	<b>4,371.1</b>	<b>16,230.4</b>	<b>8,766.6</b>	<b>16,341.1</b>
6	<b>Tax expense</b>						
	Current tax	1,369.5	1,371.7	1,233.6	3,904.2	2,560.6	4,120.0
	Deferred tax	(735.1)	(70.4)	(91.9)	(888.1)	(224.8)	(233.6)
	<b>Total tax expense</b>	<b>634.4</b>	<b>1,301.3</b>	<b>1,141.7</b>	<b>3,016.1</b>	<b>2,335.8</b>	<b>3,886.4</b>
7	<b>Profit for the period from continuing operations (5-6)</b>	<b>6,237.8</b>	<b>3,796.5</b>	<b>3,229.4</b>	<b>13,214.3</b>	<b>6,430.8</b>	<b>12,454.7</b>
<b>B</b>	<b>Discontinued Operations: (Refer note 4)</b>						
8	Profit/(loss) before tax from discontinued operations	-	484.4	(326.1)	724.9	(783.4)	(197.6)
9	Tax expense from discontinued operations	-	123.5	(84.9)	184.5	(208.7)	(47.0)
10	<b>Profit/(loss) for the period from discontinued operations (8-9)</b>	<b>-</b>	<b>360.9</b>	<b>(241.2)</b>	<b>540.4</b>	<b>(574.7)</b>	<b>(150.6)</b>
11	<b>Profit for the period (7+10)</b>	<b>6,237.8</b>	<b>4,157.4</b>	<b>2,988.2</b>	<b>13,754.7</b>	<b>5,856.1</b>	<b>12,304.1</b>
12	<b>Other comprehensive income</b>						
	Items that will not be reclassified subsequently to profit or loss:						
	(a) Re-measurement of defined benefit liability	(3.9)	(33.5)	22.4	(17.8)	67.2	78.4
	(b) Income-tax relating to items that will not be reclassified to profit or loss	1.0	8.4	(5.6)	4.5	(16.9)	(19.7)
	<b>Other comprehensive income for the period</b>	<b>(2.9)</b>	<b>(25.1)</b>	<b>16.8</b>	<b>(13.3)</b>	<b>50.3</b>	<b>58.7</b>
13	<b>Total comprehensive income for the period (11+12)</b>	<b>6,234.9</b>	<b>4,132.3</b>	<b>3,005.0</b>	<b>13,741.4</b>	<b>5,906.4</b>	<b>12,362.8</b>
14	<b>Paid-up equity share capital (face value ₹ 1 per share)</b>	<b>585.9</b>	<b>585.9</b>	<b>585.9</b>	<b>585.9</b>	<b>585.9</b>	<b>585.9</b>
15	<b>Other equity</b>						<b>178,555.8</b>
16	<b>Earnings per equity share from continuing operations (face value ₹ 1 per share)</b>	<b>(Not annualised)</b>	<b>(Not annualised)</b>	<b>(Not annualised)</b>	<b>(Not annualised)</b>	<b>(Not annualised)</b>	<b>(Annualised)</b>
	(a) Basic (in ₹)	10.65	6.48	5.51	22.55	10.98	21.26
	(b) Diluted (in ₹)	10.65	6.48	5.51	22.55	10.98	21.26
17	<b>Earnings per equity share from discontinued operations (face value ₹ 1 per share)</b>	<b>(Not annualised)</b>	<b>(Not annualised)</b>	<b>(Not annualised)</b>	<b>(Not annualised)</b>	<b>(Not annualised)</b>	<b>(Annualised)</b>
	(a) Basic (in ₹)	-	0.62	(0.41)	0.92	(0.98)	(0.26)
	(b) Diluted (in ₹)	-	0.62	(0.41)	0.92	(0.98)	(0.26)
18	<b>Earnings per equity share for total operations (face value ₹ 1 per share)</b>	<b>(Not annualised)</b>	<b>(Not annualised)</b>	<b>(Not annualised)</b>	<b>(Not annualised)</b>	<b>(Not annualised)</b>	<b>(Annualised)</b>
	(a) Basic (in ₹)	10.65	7.10	5.10	23.47	10.00	21.00
	(b) Diluted (in ₹)	10.65	7.10	5.10	23.47	10.00	21.00



K. — 4



**NOTES:**

- 1 The above standalone financial results of Aurobindo Pharma Limited ("the Company") has been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2 The above standalone financial results of the Company as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on February 10, 2024. The results for the quarter and nine months ended December 31, 2023 has been reviewed by the statutory auditors of the Company. The statutory auditors of the Company have issued an unmodified conclusion in respect of the limited review for the quarter and nine months ended December 31, 2023.
- 3 The Company operates in only one reportable segment viz., 'Pharmaceuticals' in accordance with Ind AS 108, "Operating Segment".
- 4 The Board of Directors of the Company at its meeting held on February 9, 2023 and April 1, 2023 approved the transfer of certain Active Pharmaceutical Ingredients (API) business units to its wholly owned subsidiary, Apitoria Pharma Private Limited (APPL) on a going concern basis by way of slump sale, subject to receipt of requisite regulatory approvals. Consequent to receipt of such approvals, the Company transferred the aforementioned API units to APPL with effect from October 1, 2023.

Accordingly, disclosures as required under Indian Accounting Standard (Ind AS) 105 "Non-Current Assets Held for Sale and Discontinued Operations", in the standalone financial results for all the periods have been suitably presented.

**Key financials information of discontinued Operations:**

₹ in million

Particulars	Quarter ended			Nine months ended		Year ended
	31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
Total Income	-	13,081.1	10,720.7	24,183.5	31,766.6	43,260.8
Total expenses	-	12,596.7	11,046.9	23,458.6	32,550.0	43,458.4
Profit/(loss) before tax	-	484.4	(326.2)	724.9	(783.4)	(197.6)
Total tax expense	-	123.5	(85.0)	184.5	(208.7)	(47.0)
Net profit/(loss) for the period	-	360.9	(241.2)	540.4	(574.7)	(150.6)

- 5 The Board of Directors at their meeting held on February 10, 2024 declared an interim dividend of ₹1.50 per equity share (Face value ₹ 1).

By Order of the Board



K.Nithyananda Reddy  
Vice Chairman & Managing Director  
DIN-01284195

Place: Hyderabad

Date : February 10, 2024



**INDEPENDENT AUDITOR’S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE  
FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF  
AUROBINDO PHARMA LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **AUROBINDO PHARMA LIMITED** (“the Company”), for the quarter and nine months ended December 31, 2023 (“the Statement”), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company’s Management and approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 ‘Review of Interim Financial Information Performed by the Independent Auditor of the Entity’, issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company’s personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Deloitte Haskins & Sells**  
Chartered Accountants  
(Firm’s Registration No. 008072S)

MANISH MURALIDHAR  
MURALIDHAR  
CONJEEVARAM  
Digitally signed by  
MANISH MURALIDHAR  
CONJEEVARAM  
Date: 2024.02.10  
17:15:28 +05'30'

**C Manish Muralidhar**  
(Partner)  
(Membership No. 213649)  
(UDIN: 24213649BKCJBT2064)

Place: Tirupati  
Date: February 10, 2024

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023							
	Particulars	Quarter ended			Nine months ended		Year ended
		31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1</b>	<b>Revenue from operations</b>						
	(a) Net sales/ income from operations	72,712.3	71,507.1	63,879.7	212,125.8	182,384.6	246,171.3
	(b) Other operating income	805.5	687.1	191.6	2,091.4	1,439.6	2,382.5
	<b>Total revenue from operations</b>	<b>73,517.8</b>	<b>72,194.2</b>	<b>64,071.3</b>	<b>214,217.2</b>	<b>183,824.2</b>	<b>248,553.8</b>
<b>2</b>	<b>Other income</b>						
	(a) Foreign exchange gain (net)	451.7	-	121.3	530.6	-	-
	(b) Others	1,173.5	1,869.8	805.2	3,829.8	1,783.3	2,905.9
	<b>Total other income</b>	<b>1,625.2</b>	<b>1,869.8</b>	<b>926.5</b>	<b>4,360.4</b>	<b>1,783.3</b>	<b>2,905.9</b>
	<b>Total income (1+2)</b>	<b>75,143.0</b>	<b>74,064.0</b>	<b>64,997.8</b>	<b>218,577.6</b>	<b>185,607.5</b>	<b>251,459.7</b>
<b>3</b>	<b>Expenses</b>						
	(a) Cost of materials consumed	26,755.2	27,089.1	26,214.9	81,412.6	69,819.4	96,525.1
	(b) Purchase of stock-in-trade	7,757.5	6,310.7	5,379.5	19,869.8	14,616.8	20,504.3
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(3,007.0)	(1,032.4)	(2,518.8)	(5,862.2)	(813.3)	(4,096.8)
	(d) Employee benefits expense	9,896.8	9,549.7	9,217.2	28,966.2	26,703.5	35,222.5
	(e) Finance costs	755.5	681.8	449.6	2,002.8	848.8	1,404.8
	(f) Foreign exchange loss (net)	-	297.9	-	-	622.3	395.8
	(g) Depreciation, amortisation and impairment expense	4,232.7	4,175.0	3,214.0	11,673.3	8,990.1	12,445.8
	(h) Other expenses	16,102.2	16,244.8	16,234.4	48,271.7	45,937.4	62,816.5
	<b>Total expenses</b>	<b>62,492.9</b>	<b>63,316.6</b>	<b>58,190.8</b>	<b>186,334.2</b>	<b>166,725.0</b>	<b>225,218.0</b>
<b>4</b>	<b>Profit before share of profit of associates and joint ventures, exceptional items and tax (1+2-3)</b>	<b>12,650.1</b>	<b>10,747.4</b>	<b>6,807.0</b>	<b>32,243.4</b>	<b>18,882.5</b>	<b>26,241.7</b>
<b>5</b>	Share of loss of associates and joint ventures, net of tax	(25.9)	9.0	(5.9)	(45.0)	(58.1)	(116.7)
<b>6</b>	<b>Profit before exceptional items and tax (4+5)</b>	<b>12,624.2</b>	<b>10,756.4</b>	<b>6,801.1</b>	<b>32,198.4</b>	<b>18,824.4</b>	<b>26,125.0</b>
<b>7</b>	Exceptional items (refer note 4)	-	-	-	697.5	-	-
<b>8</b>	<b>Profit before tax (6-7)</b>	<b>12,624.2</b>	<b>10,756.4</b>	<b>6,801.1</b>	<b>31,500.9</b>	<b>18,824.4</b>	<b>26,125.0</b>
<b>9</b>	<b>Tax expense</b>						
	Current tax	3,846.0	4,818.3	1,360.7	12,069.0	4,910.9	10,714.8
	Deferred tax	(621.5)	(1,581.3)	530.3	(3,184.3)	(303.9)	(3,866.3)
	<b>Total tax expense</b>	<b>3,224.5</b>	<b>3,237.0</b>	<b>1,891.0</b>	<b>8,884.7</b>	<b>4,607.0</b>	<b>6,848.5</b>
<b>10</b>	<b>Profit for the period (8-9)</b>	<b>9,399.7</b>	<b>7,519.4</b>	<b>4,910.1</b>	<b>22,616.2</b>	<b>14,217.4</b>	<b>19,276.5</b>
<b>11</b>	<b>Other comprehensive Income</b>						
	A) Items that will not be reclassified subsequently to profit or loss:						
	i) Re-measurement of defined employee benefit liability	(9.6)	(42.3)	22.4	(32.3)	71.9	79.4
	ii) Equity investments through other comprehensive income – net change in fair value	27.4	7.6	54.6	7.2	(88.1)	(65.8)
	iii) Income-tax relating to items that will not be reclassified to profit or loss	4.1	(5.9)	(5.0)	10.1	(18.6)	(19.5)
	B) Items that will be reclassified subsequently to profit or loss:						
	i) Exchange differences on translating the financial statements of foreign operations	1,865.1	554.6	4,693.8	2,112.3	7,259.8	7,361.7
	ii) Income-tax on items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-
	<b>Total other comprehensive income/(loss) for the period (net of tax)</b>	<b>1,887.0</b>	<b>514.0</b>	<b>4,765.8</b>	<b>2,097.3</b>	<b>7,225.0</b>	<b>7,355.8</b>
<b>12</b>	<b>Total comprehensive income for the period (net of tax) (10+11)</b>	<b>11,286.7</b>	<b>8,033.4</b>	<b>9,675.9</b>	<b>24,713.5</b>	<b>21,442.4</b>	<b>26,632.3</b>
	<b>Attributable to:</b>						
	Owners of the Holding Company	11,249.9	8,085.8	9,678.4	24,739.5	21,437.3	26,630.8
	Non-controlling interest	36.8	(52.4)	(2.5)	(26.0)	5.1	1.5
	<b>Out of total comprehensive income above, Profit for the year attributable to:</b>						
	Owners of the Holding Company	9,362.9	7,571.8	4,912.6	22,642.2	14,212.3	19,275.0
	Non-controlling interest	36.8	(52.4)	(2.5)	(26.0)	5.1	1.5
	<b>Other comprehensive income/(loss) attributable to:</b>						
	Owners of the Holding Company	1,887.0	514.0	4,765.8	2,097.3	7,225.0	7,355.8
	Non-controlling interest	-	-	-	-	-	-
<b>13</b>	<b>Paid-up equity share capital (face value ₹ 1 per share)</b>	<b>585.9</b>	<b>585.9</b>	<b>585.9</b>	<b>585.9</b>	<b>585.9</b>	<b>585.9</b>
<b>14</b>	<b>Other equity</b>						267,812.6
<b>15</b>	<b>Earnings per equity share (face value ₹ 1 per share)</b>	<b>(Not annualised)</b>	<b>(Not annualised)</b>	<b>(Not annualised)</b>	<b>(Not annualised)</b>	<b>(Not annualised)</b>	<b>(Annualised)</b>
	(a) Basic (in ₹)	16.04	12.83	8.38	38.60	24.26	32.90
	(b) Diluted (in ₹)	16.04	12.83	8.38	38.60	24.26	32.90



\_\_\_\_\_





**NOTES:**

- 1 The above consolidated financial results of the Group has been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2 The above consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of Companies Act, 2013 and Companies (Indian Accounting Standards) Rules, 2015, as amended.
- 3 The above consolidated financial results of the Group as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on February 10, 2024. The results for the quarter and nine months ended December 31, 2023 has been reviewed by the statutory auditors of the Company. The statutory auditors of the Company have issued an unmodified conclusion in respect of the limited review for the quarter and nine months ended December 31, 2023.
- 4 During the nine months ended December 31, 2023, the Group announced that Auro PR Inc., a step-down subsidiary based at Caguas, Puerto Rico, is undertaking restructuring of its facility to enhance production volume. The Group has accrued the severance pay due to the employees of Auro PR Inc., who are being retrenched owing to the said restructuring and disclose the same as an "exceptional item".
- 5 The Group operates in only one reportable segment viz., 'Pharmaceuticals' in accordance with Ind AS 108, "Operating Segment".
- 6 During the nine months ended December 31, 2023, Aurobindo Pharma FZ LLC, Saudi Arabia, step down subsidiary of the Company, entered into an agreement for acquisition of certain marketing and manufacturing related authorizations, for an amount of ₹ 3,983 million.
- 7 During the nine months ended December 31, 2023:
  - 1) Auro Vaccines Private Limited (wholly owned subsidiary) acquired equity shares of Tergene Biotech Limited (joint venture) from Aurobindo Pharma Limited (Parent). Consequently, Tergene Biotech Limited became a joint venture of Auro Vaccines Private Limited w.e.f April 1, 2023.
  - 2) Curateq Biologics Private Limited (wholly owned subsidiary) acquired equity shares of Auro Vaccines Private Limited (subsidiary) from Aurobindo Pharma Limited (Parent). Consequently Auro Vaccines Private limited became subsidiary of Curateq Biologics Private Limited, India w.e.f July 1, 2023
  - 3) the Group, incorporated step-down subsidiary, Auro Pharma LLC, Russia under Auroactive Pharma Private Limited (wholly owned subsidiary) w.e.f. July 24, 2023
  - 4) Consequent to regulatory approvals received during the quarter, Auroscience PTY Ltd, Australia was liquidated w.e.f. June 4, 2023.
  - 5) Pursuant to regulatory approvals received, Laboratorios Aurobindo S.L. (wholly owned subsidiary of Agile Pharma BV) merged with Aurovitas Spain SA (wholly owned subsidiary of Agile Pharma BV) w.e.f. April 1, 2023.
  - 6) Auro Trading Private Limited, India incorporated under Aurobindo Pharma Ltd, India w.e.f. November 22, 2023.
  - 7) Aurobindo Pharma Limited (Parent) acquired equity Shares of TheraNyM Biologics Private Limited from Curateq Biologics Private Limited (subsidiary). Consequently TheraNyM Biologics Private Limited became subsidiary of Aurobindo Pharma Limited, India w.e.f November 22, 2023.
  - 8) The Company transferred certain Active Pharmaceutical Ingredients units on a going concern basis to its wholly owned subsidiary, Apitoria Pharma Private Limited by way of a slump sale w.e.f October 1, 2023. This being a common control transaction under Ind AS 103 "Business Combinations", there is no impact of this transfer in the consolidated financial results.
- 8 Subsequent to the quarter end, Eugia US Manufacturing LLC (a step down subsidiary), entered into an agreement to dispose its business assets as a going concern. The transaction is expected to close within 90 days from the date of definitive agreement, subject to fulfilment of closing conditions.
- 9 The Board of Directors at their meeting held on February 10, 2024 declared an interim dividend of ₹ 1.50 per equity share (Face value ₹ 1).

By Order of the Board



K.Nithyananda Reddy  
Vice Chairman & Managing Director  
DIN-01284195

Place: Hyderabad  
Date : February 10, 2024



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF AUROBINDO PHARMA LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **AUROBINDO PHARMA LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income/loss of its associates and joint ventures for the quarter and nine months ended December 31, 2023 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of subsidiaries, associates and joint ventures listed in Annexure I.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information of 17 subsidiaries included in the unaudited consolidated financial results, whose interim financial information reflect total revenues of ₹ 38,903.4 million and ₹ 105,331.0 million for the quarter and nine months ended December 31, 2023 respectively, total profit after tax (net) of ₹ 1,692.5 million and ₹ 9,225.3 million for the quarter and nine months ended December 31, 2023 respectively and total comprehensive income (net) of ₹ 1,690.1 million and ₹ 9,217.8 million for the quarter and nine months ended December 31, 2023 respectively, as considered in the statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matters.

**Deloitte  
Haskins & Sells**

7. The unaudited consolidated financial results includes the interim financial information of 54 subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect, total revenue of ₹ 14,134.7 million and ₹ 36,769.4 million for the quarter and nine months ended December 31, 2023 respectively, total profit after tax (net) of ₹ 143.8 million and ₹ 285.6 million for the quarter and nine months ended December 31, 2023 respectively, total comprehensive Income (net) of ₹ 144.2 million and ₹ 284.8 million for the quarter and nine months ended December 31, 2023 respectively, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of loss after tax (net) of ₹ 27.1 million and ₹ 49.5 million for the quarter and nine months ended December 31, 2023 respectively and total comprehensive loss (net) of ₹ 27.1 million and ₹ 49.5 million for the quarter and nine months ended December 31, 2023 respectively, as considered in the Statement, in respect of 2 associates and 6 joint ventures, based on their interim financial information which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For **Deloitte Haskins & Sells**  
Chartered Accountants  
(Firm's Registration No. 008072S)

MANISH MURALIDHAR  
CONJEEVARAM  
Digitally signed by  
MANISH MURALIDHAR  
CONJEEVARAM  
Date: 2024.02.10  
17:14:29 +05'30'

**C Manish Muralidhar**  
Partner  
(Membership No. 213649)  
(UDIN: 24213649BKCJBU7235)

Place: Tirupati  
Date: February 10, 2024



**Annexure I to the Independent Auditor's Review Report on Review of Interim Unaudited Consolidated Financial Results**

The unaudited interim financial results include results of the following entities:

<b>S.No</b>	<b>Name of Component</b>	<b>Country</b>	<b>Relationship</b>
1	Helix Healthcare B.V.	The Netherlands	Direct Subsidiary
2	APL Pharma Thai Limited	Thailand	Direct Subsidiary
3	Aurobindo Pharma Industria Farmaceutica Ltd	Brazil	Direct Subsidiary
4	Aurobindo Pharma Produtos Farmaceuticos Limitada	Brazil	Direct Subsidiary
5	All Pharma (Shanghai) Trading Co Ltd	China	Direct Subsidiary
6	Aurobindo Pharma USA Inc.	USA	Direct Subsidiary
7	APL Healthcare Limited	India	Direct Subsidiary
8	Auronext Pharma Private Limited	India	Direct Subsidiary
9	Auro Peptides Ltd	India	Direct Subsidiary
10	Apitoria Pharma Private Limited	India	Direct Subsidiary
11	Auroactive Pharma Private Limited	India	Direct Subsidiary
12	CuraTeQ Biologics Private Limited	India	Direct Subsidiary
13	AuroZest Private Limited	India	Direct Subsidiary
14	Aurobindo Antibiotics Private Limited	India	Direct Subsidiary
15	Eugia Pharma Specialities Ltd	India	Direct Subsidiary
16	Mviyes Pharma Ventures Private Limited	India	Direct Subsidiary
17	GLS Pharma Private Limited	India	Direct Subsidiary
18	TheraNyM Biologics Private Limited	India	Direct Subsidiary
19	Auro Trading Private Limited (w.e.f November 22, 2023)	India	Direct Subsidiary
20	Auro Vaccines Private Limited	India	Step-Down Subsidiary
21	Agile Pharma B.V.	The Netherlands	Step-Down Subsidiary
22	Laboratorios Aurobindo S.L. (merged with Aurovitas Spain w.e.f. April 01, 2023)	Spain	Step-Down Subsidiary
23	Aurex B.V.	The Netherlands	Step-Down Subsidiary
24	Milpharm Limited	U.K.	Step-Down Subsidiary
25	Aurobindo Pharma (Malta) Ltd	Malta	Step-Down Subsidiary
26	APL Swift Services (Malta) Ltd	Malta	Step-Down Subsidiary
27	Aurobindo Pharma (Romania) s.r.l	Romania	Step-Down Subsidiary
28	Pharmacin B.V.	The Netherlands	Step-Down Subsidiary
29	Aurovitas Pharma Polska	Poland	Step-Down Subsidiary
30	Generis Farmaceutica S.A.	Portugal	Step-Down Subsidiary
31	Generis Phar, Unipessoal Lda	Portugal	Step-Down Subsidiary
32	Aurobindo Pharma (Italia) S.r.l	Italy	Step-Down Subsidiary
33	Arrow Generiques SAS	France	Step-Down Subsidiary
34	1980 Puren Pharma GmbH, Germany	Germany	Step-Down Subsidiary
35	Puren Pharma GmbH & Co., KG	Germany	Step-Down Subsidiary
36	Aurovitas Spain SA	Spain	Step-Down Subsidiary
37	Aurobindo Pharma B.V.	The Netherlands	Step-Down Subsidiary
38	Aurovitas Spol s.r.o	Czech Republic	Step-Down Subsidiary
39	Apotex Europe B.V.	The Netherlands	Step-Down Subsidiary
40	Aurovitas Nederland B.V	The Netherlands	Step-Down Subsidiary
41	Sameko Farma B.V.	The Netherlands	Step-Down Subsidiary
42	Leidapharm B.V.	The Netherlands	Step-Down Subsidiary
43	Marel B.V.	The Netherlands	Step-Down Subsidiary
44	Pharma Dossier B.V.	The Netherlands	Step-Down Subsidiary
45	Aurobindo NV/SA	Belgium	Step-Down Subsidiary
46	CuraTeQ Biologics s.r.o.	Czech Republic	Step-Down Subsidiary
47	Eugia Pharma B.V.	The Netherlands	Step-Down Subsidiary
48	Eugia Pharma (Malta) Limited	Malta	Step-Down Subsidiary
49	Eugia (UK) Limited	U.K.	Step-Down Subsidiary
50	Auro Pharma Inc.	Canada	Step-Down Subsidiary
51	Aurobindo Pharma (Pty) Ltd	South Africa	Step-Down Subsidiary
52	Aurobindo Pharma Japan KK	Japan	Step-Down Subsidiary
53	Aurovida Farmaceutica SA DE CV	Mexico	Step-Down Subsidiary
54	Aurobindo Pharma Colombia S.A.S	Colombia	Step-Down Subsidiary

**Deloitte  
Haskins & Sells**

S.No	Name of Component	Country	Relationship
55	Aurogen South Africa (PTY) Ltd	South Africa	Step-Down Subsidiary
56	Aurobindo Pharma Saudi Arabia Limited Company	Saudi Arabia	Step-Down Subsidiary
57	Aurovitas Pharma (Taizhou) Ltd	China	Step-Down Subsidiary
58	Aurobindo Pharma FZ-LLC	Dubai	Step-Down Subsidiary
59	Aurosulud SA De CV	Mexico	Step-Down Subsidiary
60	Auro PR Inc.	Puerto Rico	Step-Down Subsidiary
61	Eugia Pharma Inc.	Canada	Step-Down Subsidiary
62	Eugia Pharma (Australia) PTY Limited	Australia	Step-Down Subsidiary
63	Eugia Pharma Industria Farmaceutica Limitada	Brazil	Step-Down Subsidiary
64	Aurobindo Pharma Ukraine LLC	Ukraine	Step-Down Subsidiary
65	Eugia Pharma Colombia S.A.S.	Colombia	Step-Down Subsidiary
66	PT Aurogen Pharma	Indonesia	Step-Down Subsidiary
67	Auroscience PTY Ltd (liquidated w.e.f June 04, 2023)	Australia	Step-Down Subsidiary
68	Aurolife Pharma LLC	USA	Step-Down Subsidiary
69	Auro Health LLC	USA	Step-Down Subsidiary
70	Auro AR LLC	USA	Step-Down Subsidiary
71	Auro Vaccines LLC	USA	Step-Down Subsidiary
72	AuroLogistics LLC	USA	Step-Down Subsidiary
73	Acrotech Biopharma Inc	USA	Step-Down Subsidiary
74	Auro Science LLC	USA	Step-Down Subsidiary
75	Auro Packaging LLC	USA	Step-Down Subsidiary
76	Vespyr Brands, Inc	USA	Step-Down Subsidiary
77	Eugia Inc.	USA	Step-Down Subsidiary
78	Eugia US LLC	USA	Step-Down Subsidiary
79	Eugia US Manufacturing LLC	USA	Step-Down Subsidiary
80	Eugia Steriles Private Limited	India	Step-Down Subsidiary
81	Lyfius Pharma Private Limited	India	Step-Down Subsidiary
82	Qule Pharma Private Limited	India	Step-Down Subsidiary
83	Eugia SEZ Private Limited	India	Step-Down Subsidiary
84	Auro Pharma LLC (w.e.f July 24, 2023)	Russia	Step-Down Subsidiary
85	Novagen Pharma (Pty) Ltd	South Africa	Joint venture
86	Purple Bellflower, South Africa	South Africa	Joint venture
87	Luoxin Aurovitas Pharm (Chengdu) Co. Ltd.	China	Joint venture
88	Novagen BBBEE Invest Co (Pty) Ltd	South Africa	Joint venture
89	Raidurgam Developers Limited	India	Joint venture
90	Tergene Biotech Limited	India	Joint venture
91	NVNR (Ramannapet I) Power Plant Private Limited	India	Associate
92	NVNR (Ramannapet II) Power Plant Private Limited	India	Associate